SYGN 313
Alternative Names: SYGN-313Latest Information Update: 12 Sep 2023
At a glance
- Originator Synedgen
- Class Antibacterials; Polysaccharides
- Mechanism of Action Inflammation mediator inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Crohn's disease; Inflammatory bowel diseases
Most Recent Events
- 12 Sep 2023 SYGN 313 is still in preclinical development for Crohn's disease and Inflammatory bowel diseases in USA (PO) (Synedgen pipeline, September 2023)
- 28 Aug 2020 No recent reports of development identified for preclinical development in Crohn's-disease in USA (PO)
- 28 Aug 2020 No recent reports of development identified for preclinical development in Inflammatory-bowel-diseases in USA (PO)